Telo Genomics Corp
Research Telo Genomics Corp (3D0A) on Bullrun: market cap EUR 50.22K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3D0A
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyEUR
- Market capEUR 50.22K
- Financial periodQ1 2026
- RevenueCAD 0
- Net income-CAD 560.48K
- Free cash flow-CAD 325.61K
Valuation Snapshot
latest market cap is EUR 50.22K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 2.62M | -CAD 2.20M | n/a | n/a | CAD 50.11K | CAD 161.31K | -CAD 553.33K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 50.22K | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Telo Genomics Corp
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Telo Genomics Corp's market cap?
Telo Genomics Corp's market capitalization is EUR 50.22K.
What does Telo Genomics Corp do?
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments.